Physician profile

Douglas Hardesty

Neurological Surgery · Columbus, OH

NPI 1013203835

$11,605.49

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$394.29
Food and Beverage$216.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Siemens Medical Solutions USA, INC. $10,910.53 2022
Stryker Corporation $394.29 2023 Everest Spinal System
Gt Medical Technologies, INC $155.64 2023 Gammatile
Integra Lifesciences Corporation $84.60 2019
Aesculap, INC. $29.36 2023 M.Blue
Innovation Technologies INC $17.68 2023 Irrisept
Hyperfine Operations, INC. $13.39 2023 Swoop

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Douglas Hardesty

$11,605.49

in general payments reported 2019-2025

Years
2019-2023
Top company
Siemens Medical Solutions USA, INC.

https://glasscript.com/doctor/182144/douglas-hardesty

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.